Empowered Antibodies 2013 |
Friday, 14 May 2013
The Stevenage Bioscience Catalyst
Gunnels Wood Road, Stevenage , Hertfordshire, United Kingdom
The aim of this event is to discuss new ideas to accelerate antibody-drug conjugates, bispecifics and other empowered antibody therapies to the clinic.
This event has CPD accreditation
This event is part of the 2013 Euroscicon BioTherapeutics Week,
to find out more see www.biotherapeutics2013.com
This event has CPD accreditation
Meeting chair
Professor Roy Jefferis, PhD; CChem, FRSC; MRCP; FRCPath; DSc
Professor Emeritus: Molecular Immunology School of Immunity & Infection University of Birmingham B15 2TT UK
Who Should Attend
Biotech and Pharma Industry: CEOs, Chief Scientists, Group Heads, Senior and Junior Scientists, Research
Academic and Research Institutes: Group and Lab Heads, Postdoctoral Scientists and Research Students
People working in
- Antibody Development
- Antibody Discovery
- Antibody Engineering
- Formulation Development
- Biologics
- Monoclonal antibody operations
- Immunoassay development
- Protein Engineering
- Translational Research
- Discovery Chemistry
- Molecular Medicine
- Molecular Discovery Research
- Molecular Biology and Chemistry
- Regulatory Affairs
- Business Development
- Genomics
9:00 – 9:45 Registration
9:45 – 10:00 Introduction by the Chairs: Professor Roy Jefferis, PhD; CChem, FRSC; MRCP; FRCPath; DSc
Professor Emeritus: Molecular Immunology School of Immunity & Infection University of Birmingham B15 2TT UK
10:00 – 10:30 Radionuclide imaging and therapy with antibodies
Professor Phil Blower, Kings College London, UK
Radiolabelling antibodies and antibody fragments with gamma and positron emitting radionuclides serves is valuable both for diagnostic imaging in patient management (for detection/localisation of disease, and for studying the in vivo biological behaviour and distribution of therapeutic antibodies. With suitable beta or alpha emitting radionuclides it can also be applied in targeted radionuclide therapy of cancer. This presentation will outline examples of these applications under development, and some of the methods for radiolabelling with different radionuclides.
10:30 – 11:00 Antibody-directed Phototherapy
Dr Mahendra Deonarain, Imperial College, London
11:00 – 11:30 Speakers’ photo then mid-morning break and trade show
Please try to visit all the exhibition stands during your day at this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
11:30 – 12:00 Patient humoral immune responses and the design of antibodies with improved effector functions for cancer therapy
Dr Sophia N Karagiannis, St. John’s Institute of Dermatology, King’s College London School of Medicine, UK
Immune activatory and effector functions contribute to anti-tumoural efficacy of clinically-approved therapeutic antibodies. This presentation will highlight key elements of our approach towards developing antibodies with improved effector functions and efficacy, encompassing: a) elucidating antibody mechanisms of action in disease-relevant models; b) dissecting humoral (B cell and antibody) responses and antibody-blocking mechanisms in patients; c) evaluating the potential clinical applicability of different antibody classes, including those with potent effector functions such as antibodies engineered with Fc regions of the IgE class. Our anti-Folate Receptor alpha antibody in pre-clinical development supported by the CR-UK New Agents Committee is a paradigm for the latter concept. Elucidating immune escape mechanisms harbours the potential to inform the rational design of antibodies less prone to tumour-induced blockade.
12:00 – 12:30 To be confirmed
12:30 – 13:30 Lunch and trade show
Please try to visit all the exhibition stands during your day at this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
13:30 – 14:30 Question and Answer Session
Delegates will be asked to submit questions to a panel of experts. Questions can be submitted before the event or on the day
14:30 – 15:00 Afternoon Tea/Coffee and trade show
15:00– 15:30 Antibody directed enzyme prodrug systems for cancer therapy
Dr Surinder K Sharma, Head: ADEPT & Translational Therapeutics, UCL Cancer Institute
15:30 - 16:00 To be confirmed
16: 00 - 16:30 Targeted co-delivery of antigens and adjuvants to dendritic cells for anti-tumour immunity induction
Dr. Sandra Diebold, Guy’s Hospital London
The initiation of immune responses is dependent on innate immune activation via sensors that detect molecular structures associated with certain pathogens. In case of viral infections, viral nucleic acids serve as molecular signatures that trigger innate immune activation. We explore synthetic mimics of viral nucleic acids as adjuvants for the induction of anti-tumour immunity. We investigate antibody-antigen-adjuvant conjugates for co-deliver antigens and nucleic acid adjuvants to C-type lectin receptor-expressing dendritic cells. This approach proved to be more efficient in inducing cytotoxic T lymphocytes than co-injection of antibody-antigen conjugates with soluble adjuvant and led to effective anti-tumour immunity in a proof-of-principal mouse model
16:30 – 17:00 Chairman’s summing up
About the Speakers
After studying Natural Sciences at Cambridge University, Phil Blower completed a DPhil in transition-metal chemistry University of Sussex in 1984. After postdoctoral research at Indiana University on a Fulbright Scholarship, and then at Oxford University, in 1987 he joined the National Health Service as Clinical Radiochemist with Kent and Canterbury Hospital (Nuclear Medicine) and University for Kent (Biosciences), combining inorganic chemistry with nuclear medicine, developing research programmes in radiochemistry and bioconjugate synthesis, leading to some of the earliest clinical evaluations of rhenium-186 and rhenium-188 therapeutic agents. In 2006 he was appointed Professor of Imaging Chemistry at King’s College London.
Sandra Diebold has studied Biology at the Eberhardt-Karls University in Tübingen and received her PhD from the Free University Berlin for her thesis on receptor-mediated gene transfer into dendritic cells. As a PhD student she worked in Martin Zenke’s laboratory at the Institute for Molecular Pathology in Vienna and at the Max-Delbrück Center in Berlin. She subsequently joined Caetano Reis e Sousa’s laboratory at the Cancer Research UK London Research Institute as a postdoctoral fellow, where she studied mechanisms of viral recognition by dendritic cells. Since 2006 she is a lecturer in the Peter Gorer Department of Immunobiology at King’s College London, School of Medicine. Her group is exploring the use of synthetic mimics of viral nucleic acids as adjuvants for tumour immunotherapy.
Sophia Karagiannis is a translational cancer immunologist specialising in antibody therapies for melanoma, ovarian and breast carcinomas. She received BA and MS degrees at Rutgers University, USA, having received scholarship awards and a teaching assistantship (1987, 1991), and a PhD at King’s College London in Biochemistry under SERC and SmithKline Beecham-funded scholarships (1995). She subsequently developed immunotherapeutic strategies for cancer and inflammatory diseases in academic and biotechnology environments in London and Cambridge as a postdoctoral associate and scientific investigator. She was appointed as NIHR Senior Research Fellow in 2007 and presently leads her own research group as Head of Cancer Antibody Discovery and Immunotherapy at King’s College London, focused on dissecting humoral immunity in cancer and leading research into tumour-targeting mechanisms of IgE antibodies and Th2 responses in cancer. Sophia co-founded the International Task Force on AllergoOncology and has pioneered IgE therapeutics for solid tumours. Her research and development initiative on the first IgE class antibody for cancer therapy is conducted in close collaboration with clinical and academic groups at King’s College London and the CR-UK Drug Development Office.
Registration Web Site: www.regonline.co.uk/ADC2013
Post expires at 8:19am on Tuesday May 14th, 2013
Follow Us!